#NSCLC is an active hashtag on Bluesky. In the last 30 days, 25 people shared 41 posts with it — around 1 a day. Activity is down 33% versus the previous week, peaking on Jul 31 with 4 posts.
www.youtube.com
OncoAlert Video Journal: Dr.Ricciuti/Deep Learning Model for Predicting IO ResponseNSCLC Lung Cancer
YouTube video by OncoAlert 360
oncodaily.com
5 papers about Lung Cancer suggested by Stephen Liu - OncoDaily
5 papers about Lung Cancer suggested by Stephen Liu / Alessandro Brunelli, Anne Gulbech Ording, cancer, Dániel Sztankovics, Georgetown University, Jii Bum
oncodaily.com
Highlights from ELCC Day 3 - OncoDaily
Highlights from ELCC Day 3 / Alessandra Dodi, Alfredo Addeo, Amol Akhade, Antonio Calles, cancer, ELCC, ELCC 2025, ELCC25, Eric Halioua, ESMO, Giannis
oncodaily.com
Amy C. Moore: 2024 was an exciting year for lung cancer advances - OncoDaily
Amy C. Moore: 2024 was an exciting year for lung cancer advances / Amy C. Moore, cancer, Cell, EGFR, Lung cancer, medicine, NSCLC, OncoDaily, Oncology, patients
www.onclive.com
LCT Gains Ground in EGFR-Mutated NSCLC | OncLive
Eric K. Singhi, MD, and Kyle G. Mitchell, MD, MSc, discuss the present and future role of LCT in NSCLC.
www.pulmonologyadvisor.com
Surgical Resection After Immunochemotherapy in NSCLC May Improve Survival
In NSCLC, surgical resection after induction immunochemotherapy was associated with improved survival compared with definitive radiotherapy.
www.onclive.com
FDA Grants Breakthrough Therapy Designation to Olomorasib in KRAS G12C+ Pancreatic Cancer | OncLive
Olomorasib earned breakthrough therapy status as a monotherapy for adults with previously treated, KRAS G12C-mutant advanced pancreatic cancer.
pharmaphorum.com
UK patient first in world to get novel lung cancer vaccine
A woman from the Wirral in the UK has become the first patient in the world to receive an experimental, personalised neoantigen lung cancer vaccine.
jamanetwork.com
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non–Small Cell Lung Cancer
This randomized trial assesses the effect of ivonescimab added to chemotherapy on overall survival among patients with EGFR-variant non–small cell lung cancer (NSCLC) who had disease progression with ...
European Organisation for Research and Treatment of Cancer @eortc.org
🎗️ Tomorrow is #WorldLungCancerDay. A recent Lung Cancer publication shows that the EORTC QLQ-C30 and QLQ-LC29 capture many common patient-reported symptomatic adverse events in #NSCLC, supporting the use of PROs alongside clinician-reported assessments. www.eortc.org/publications/ @qol.eortc.org
nature.com
Dual targeting of BCL-XL and MCL-1 exposes a rapid and exploitable apoptotic vulnerability in non-small cell lung cancer - Cell Death & Differentiation
Cell Death & Differentiation - Dual targeting of BCL-XL and MCL-1 exposes a rapid and exploitable apoptotic vulnerability in non-small cell lung cancer
Posts are pulled live from Bluesky and cached briefly. Posts with content labels are hidden.
